Thomassin J, Tephly T R
Department of Pharmacology, University of Iowa, Iowa City 52242.
Mol Pharmacol. 1990 Sep;38(3):294-8.
Benzodiazepines have been shown to competitively inhibit morphine glucuronidation in rat and human hepatic microsomes. Flunitrazepam exerted a potent competitive inhibition of rat hepatic morphine UDP-glucuronosyltransferase (UDPGT) activity (Ki = 130 microM). It has no effect on the activity of p-nitrophenol, 17 beta-hydroxysteroid, 3 alpha-hydroxysteroid, or 4-hydroxybiphenyl UDPGTs. Because flunitrazepam is an effective photoaffinity label for benzodiazepine receptors, studied were performed in solubilized rat hepatic microsomes and with partially purified preparations of morphine UDPGT to determine the enhancement of flunitrazepam inhibition and binding to morphine UDPGT promoted by exposure to UV light. Under UV light, flunitrazepam inhibition was markedly enhanced. UV light exposure also led to a marked increase in binding of [3H]flunitrazepam to microsomal protein, which was protected substantially by preincubation with morphine. Testosterone, androsterone, and UDP-glucuronic acid did not protect against UV-enhanced flunitrazepam binding, and morphine did not reverse flunitrazepam binding once binding had occurred. As morphine UDPGT was purified, a good correlation was found between the increases in specific activity of morphine UDPGT and flunitrazepam binding to protein. Chromatofocusing chromatography showed that flunitrazepam bound only to fractions containing active morphine UDPGT, and no binding to 4-hydroxybiphenyl UDPGT was observed. Fluorography of a sodium dodecyl sulfate-polyacrylamide electrophoresis gel of solubilized hepatic microsomes that had been treated with [3H] flunitrazepam under UV light revealed a band with a monomeric molecular weight between 54,000 and 58,000. This monomeric molecular weight compares favorably with the reported monomeric molecular weight of homogeneous morphine UDPGT (56,000). These studies suggest that flunitrazepam binds rather selectively to the morphine binding site of morphine UDPGT and may prove to be a useful probe for this enzyme.
苯二氮䓬类药物已被证明能在大鼠和人肝微粒体中竞争性抑制吗啡葡萄糖醛酸化。氟硝西泮对大鼠肝脏吗啡尿苷二磷酸葡萄糖醛酸基转移酶(UDPGT)活性有强效竞争性抑制作用(Ki = 130微摩尔)。它对对硝基苯酚、17β - 羟基类固醇、3α - 羟基类固醇或4 - 羟基联苯UDPGTs的活性没有影响。由于氟硝西泮是苯二氮䓬受体的有效光亲和标记物,因此在溶解的大鼠肝微粒体和部分纯化的吗啡UDPGT制剂中进行了研究,以确定暴露于紫外线下氟硝西泮抑制作用和与吗啡UDPGT结合的增强情况。在紫外线下,氟硝西泮的抑制作用明显增强。紫外线照射还导致[3H]氟硝西泮与微粒体蛋白的结合显著增加,预先与吗啡孵育可对此起到很大的保护作用。睾酮、雄酮和尿苷二磷酸葡萄糖醛酸不能防止紫外线增强的氟硝西泮结合,并且一旦发生结合,吗啡不能逆转氟硝西泮的结合。随着吗啡UDPGT的纯化,发现吗啡UDPGT比活性的增加与氟硝西泮与蛋白的结合之间存在良好的相关性。色谱聚焦层析表明,氟硝西泮仅与含有活性吗啡UDPGT的组分结合,未观察到与4 - 羟基联苯UDPGT的结合。在紫外线下用[3H]氟硝西泮处理的溶解肝微粒体的十二烷基硫酸钠 - 聚丙烯酰胺电泳凝胶的荧光自显影片显示出一条带,其单体分子量在54,000至58,000之间。这个单体分子量与报道的纯吗啡UDPGT的单体分子量(56,000)相当。这些研究表明,氟硝西泮相当选择性地结合到吗啡UDPGT的吗啡结合位点,可能被证明是该酶的一种有用探针。